|1.||Risède, Patricia: 3 articles (03/2013 - 05/2006)|
|2.||Mégarbane, Bruno: 3 articles (03/2013 - 05/2006)|
|3.||Baud, Frédéric J: 3 articles (03/2013 - 05/2006)|
|4.||Schlatter, Joel: 2 articles (03/2013 - 12/2012)|
|5.||Tournier, Nicolas: 2 articles (03/2013 - 12/2012)|
|6.||Chiadmi, Fouad: 2 articles (03/2013 - 12/2012)|
|7.||Smirnova, Maria: 2 articles (03/2013 - 12/2012)|
|8.||Cisternino, Salvatore: 2 articles (03/2013 - 12/2012)|
|9.||Alhaddad, Hisham: 2 articles (03/2013 - 12/2012)|
|10.||Moody, David E: 2 articles (11/2011 - 05/2007)|
11/01/2006 - "Effects of intermittent hemodialysis on buprenorphine and norbuprenorphine plasma concentrations in chronic pain patients treated with transdermal buprenorphine."
11/01/2006 - "The present study was designed to study the impact of intermittent hemodialysis on the disposition of the partial agonist buprenorphine and its metabolite norbuprenorphine during therapy with transdermal buprenorphine in chronic pain patients with end-stage kidney disease. "
|2.||Chronic Kidney Failure (Chronic Renal Failure)
|3.||Respiratory Insufficiency (Respiratory Failure)
05/01/2007 - "No saturation of the effect at high concentrations was observed, indicating that norbuprenorphine acts as a full agonist with regard to respiratory depression. "
05/01/2006 - "Norbuprenorphine 3 mg kg(-1) produces the rapid onset of sustained respiratory depression, as demonstrated at 20 min by a maximal significant increase in PaCO(2) (8.4+/-0.9 versus 5.7+/-0.1 kPa), decrease in arterial pH (7.25+/-0.06 versus 7.44+/-0.01), and hypoxia (8.3+/-0.6 versus 11.1+/-0.2 kPa). "
01/01/2015 - "We propose that in the context of prior toxic impregnation, buprenorphine directly (and not via its metabolite norbuprenorphine) acted as a triggering factor by blocking the ventilatory response, rapidly leading to fatal respiratory depression. "
12/01/2012 - "Norbuprenorphine(≥ 1 mg/kg) and to a lesser extent buprenorphine (≥ 10 mg/kg) were responsible for dose-dependent respiratory depression combining increased inspiratory (TI) and expiratory times (TE). "
10/01/2012 - "Compared with buprenorphine, norbuprenorphine causes minimal antinociception but greater respiratory depression. "
|4.||Neonatal Abstinence Syndrome
04/01/2010 - "Statistically significant correlations were observed for mean maternal daily dose from enrollment to delivery and placenta buprenorphine-glucuronide concentration and for norbuprenorphine-glucuronide concentrations and time to neonatal abstinence syndrome onset and duration, for norbuprenorphine/norbuprenorphine-glucuronide ratio and maximum neonatal abstinence syndrome score, and newborn length. "
11/01/2008 - "Total buprenorphine meconium concentrations and buprenorphine/norbuprenorphine ratios were significantly related to neonatal abstinence syndrome (NAS) scores >4. As free buprenorphine concentration and percentage free buprenorphine increased, head circumference decreased. "
|5.||Renal Insufficiency (Renal Failure)
|2.||delta Opioid Receptors (delta Opioid Receptor)
|3.||Hypnotics and Sedatives (Sedatives)
|4.||Opioid Analgesics (Opioids)
|1.||Renal Dialysis (Hemodialysis)